Shang Hai Zheng Quan Bao·2026-02-26 18:52Group 1 - The core point of the announcement is that Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has received approval from the China Securities Regulatory Commission (CSRC) to publicly issue technology innovation corporate bonds with a total face value of up to RMB 6 billion [1][2] - The approval is valid for 24 months from the date of registration, allowing the company to issue the bonds in tranches based on funding needs and market conditions [1][3] - The company commits to fulfilling disclosure obligations in accordance with relevant laws and regulations during the bond issuance process [1][2] Group 2 - The company has also conducted a self-examination regarding insider trading related to the planned spin-off of its subsidiary, Fosun Antigen (Chengdu) Biopharmaceutical Co., Ltd., for listing on the Hong Kong Stock Exchange [3][4] - The self-examination period for insider trading was set from April 28, 2025, to January 22, 2026, covering the time before the board's first resolution on the spin-off [5][6] - The company confirmed that no insider trading occurred during the self-examination period, and necessary confidentiality measures were implemented to control the range of insider information [19][20]